Applied Nutrition PLC™ Launches Multi-Feature Innovation With TANG® Drink Brand
Combining poignant nostalgia with modern wellness benefits, AN SUPPS™ rolls out TANG® co-branded sports nutrition products – in multiple formats and flavors – across North America. TANG® - leveraging the industry know-how, manufacturing and distribution from AN SUPPLEMENTS™ – extends into sports nutrition for the first time .
Fans of the iconic TANG® flavors – and generations who grew up with tubs of original TANG® drink mix– can now turn to the brand's beloved Orange and Orange Strawberry varieties as they fulfill critical needs in sports nutrition.
Beginning with carbonated, ready to drink canned energy beverages, AN SUPPS™ will be rolling out co-branded TANG® Orange and TANG® Orange Strawberry, through its own direct to consumer website www.ansupps.com, Amazon and coolers across America within gyms, and specialty retail. Launches of the energy beverage at other retailers are quickly forthcoming. Next month, AN SUPPS™ will launch TANG® co-branded pre-workout powder, caffeine free pre-workout powder, and hydration powder, in the same Orange flavor format exclusively with The Vitamin Shoppe – Find these products Nationwide!
'Since 1957, TANG has a rich history of creating smiles with every sip,' said Charter Foster, Senior Licensing Manager for Kraft Heinz. 'In partnership with AN SUPPS™, we're excited to leverage their innovative products with the unique equities and nostalgia of TANG to drive conversation and excitement for the brand in new beverage categories and bring this same experience to the sports nutrition aisle.'
Anyone thirsty for a refreshing, tangy can of TANG® energy drink from AN SUPPS™ can head to www.ansupps.com or Amazon to either purchase their fill of TANG® sports nutrition, or to find other retail locations where the beverage is being sold. The refreshing drink is gluten free, sugar-free, and boasts natural flavors as well as Citrulline which helps enhance endurance, reduce muscle fatigue and improve high-intensity exercise. The addition of Betaine Anhydrous allows TANG® energy drinks to help increase metabolism and augment muscle strength.
'We are thrilled with the alliance that AN SUPPS™ has established with TANG®,' said Aaron Heidebreicht, CEO of AN SUPPS a division of Applied Nutrition PLC, UK . 'TANG® is one of many brands – and canned energy beverages, the first of many formats – that allow our corporations to equitably share our respective marketplace strengths,' Heidebreicht continued. 'Furthermore, the brand is a wink to anyone taking care of themselves in the present, while wistful of the brands they have enjoyed in the past,' Heidebreicht said.
To experience more of the tangy news regarding TANG® co-branded sports nutrition, please visit www.ansupps.com as well as the AN SUPPS™ social media feeds through Facebook, Instagram, You Tube and Tik Tok.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
$1M Lottery Powerball ticket won in Pa.
(WBRE/WYOU) — A lucky lottery player has won $1 million off a Powerball ticket in Pennsylvania. A Pennsylvania Lottery retailer in Carbon County sold a Powerball® ticket worth $1 million for the Monday, August 4, drawing. The ticket matched five of the five white balls drawn, 8-9-19-31-38, but not the red Powerball® 21, to win $1 million. $1M won off $20 lottery scratch-off ticket in Pa. Boyer's Food Markets in Lansford Boro will receive a $5,000 bonus for selling the winning ticket. Winners are not known until prizes are claimed and tickets are validated. Pennsylvania Lottery Powerball® winners have one year from the drawing date to claim prizes. Winning tickets purchased at a Lottery retailer should immediately be signed on the back. Online winnings automatically appear in a player's account after the claim has been processed. Players may visit for more information about how to file a claim. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI). Managing blood pressure instability is a major unmet need after SCI, with a significant impact on cardiovascular health and quality of life. Approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe are expected to participate. EINDHOVEN, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption for the ARC-IM System. With this approval, the Company can initiate the Empower BP pivotal study to assess the safety and efficacy of its implantable spinal stimulation system to address blood pressure instability after SCI. Empower BP is the Company's second global pivotal study, and the first to evaluate the implantable ARC-IM System. The randomized, double-blinded, sham-controlled study is expected to involve approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe, with first patient enrollment anticipated before the end of the year. The study will target participants with injuries at spinal cord levels C2-T6, injury severities of AIS A-D, and blood pressure instability characterized by chronic orthostatic hypotension (OH) and episodes of autonomic dysreflexia (AD). 'This is an important milestone for ONWARD and the SCI community,' said Dave Marver, CEO of ONWARD. 'Our ARC-IM System is designed to address several unmet needs, including blood pressure instability which is a major recovery target after spinal cord injury. With this IDE approval, we continue to advance our innovation pipeline and inspire realistic hope in restoring autonomic functions and independence after SCI and other movement disabilities.' Over 50% of people with SCI experience blood pressure instability, affecting nearly 350,000 people in the US and Europe.1 Blood pressure instability and persistent low blood pressure can threaten neurological recovery and negatively impact cardiovascular health and quality of life. The most frequent symptoms include dizziness, lightheadedness, blurred vision and fatigue.2 'Blood pressure instability, especially chronic low blood pressure, is one of the most hidden and unrecognized functional complications of spinal cord injury,' explains Dr. James Guest, neurosurgeon and Professor of Neurological Surgery at the University of Miami. 'It leaves people feeling unwell and can significantly impact their overall quality of life. Blood pressure instability also increases the risk of cardiovascular disease, making addressing this unmet need critical for improving the long-term outcomes of SCI.' The ONWARD ARC-IM System is an implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation. It is the first neuroprosthetic system designed to manage blood pressure instability in people with SCI. It comprises the implanted ONWARD Neurostimulator (IPG) and the ARC-IM Thoracic Lead. The ARC-IM Thoracic Lead is optimized for surgical placement in a specific region of the thoracic spinal cord, called the 'Hemodynamic Hotspot'. The location was first discovered by the Company's research partners at the Swiss Federal Institute of Technology Lausanne (EPFL), Centre Hospitalier Universitaire Vaudois (CHUV), and the University of Calgary in a study published in Nature in January 2021.3 In December 2022, the Company announced positive top-line interim clinical results from its feasibility studies showing improved blood pressure regulation and improved hemodynamic stability after SCI. In addition to immediate and sustained improved blood pressure levels, participants taking anti-hypotension drugs prior to the study significantly reduced or discontinued their medication. Participants also reported improved general well-being and a reduction in orthostatic hypotension, including reduced dizziness and increased energy. Detailed interim results from these studies are expected to be published later this year. Managing blood pressure instability is among the major unmet needs for which the FDA has awarded the Company one of its 10 Breakthrough Device Designations. This award is reserved for novel, cutting-edge therapies addressing unmet needs and provides potential regulatory and reimbursement benefits. To stay informed about ONWARD's research studies, technologies, and the availability of therapies in your area, please complete this webform. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries, and other movement disabilities. Building on over a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed ARC Therapy. It has subsequently been awarded 10 Breakthrough Device designations from the FDA. The Company's ARC-EX® System is cleared for commercial sale in the US. The Company is also developing an investigational implantable system called ARC-IM, which can be paired with a brain-computer interface (BCI) to restore thought-driven movement. Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, please visit For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Notes and references: 1. Katzelnick CG et al. Blood Pressure Instability in Persons With SCI: Evidence From a 30-Day Home Monitoring Observation. Am J Hypertens. 2019 Sep 24;32(10):938-944 2. Carlozzi, N. E. et al. Impact of blood pressure dysregulation on health-related quality of life in persons with spinal cord injury: development of a conceptual model. Arch. Phys. Med. Rehabil. 94, 1721–1730 (2013) 3. Squair, J.W. et al. Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury. Nature 590, 308–314 (2021) Forward-Looking Statements Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Nordson Electronics Solutions 將於 SEMICON Taiwan 2025 展示面板級與晶圓級封裝的高產量流體點膠技術
加州卡爾斯巴德--(BUSINESS WIRE)--(美國商業資訊)-- Nordson Electronics Solutions 作為全球可靠電子製造技術的領導者，將於 9 月 10 至 12 日在 SEMICON Taiwan 2025 的 i2326 展位，展示其最新的 半導體製造設備 。 展品包括 ASYMTEK ® Vantage ® 點膠系統 ，配置兩個 ASYMTEK IntelliJet ® 噴射閥 ，專為半導體封裝及微電子製造提供高效精準的生產方案。Vantage 系統提供多種創新配置，以滿足當前技術發展需求，例如面板級封裝。該系統已廣泛應用於晶圓級封裝作業，包括高產量底部填充、間隙填充，以及適用於扇出/扇入、基板及模組組裝的密封生產線。 等離子處理可去除雜質並活化表面，增強流動性與附著力，從而提升半導體封裝的可靠性。Nordson 等離子處理專家將在現場與客戶探討，如何利用該技術成功實現先進封裝作業。 SEMICON Taiwan 2025 的主題為 「世界同行，創新啟航」，將展示半導體社群如何應對供應鏈變化，以及業界如何為當前與未來開發解決方案。 Nordson Electronics Solutions 致力讓可靠電子產品成為現實。我們透過 ASYMTEK、MARCH 及 SELECT 品牌，為全球半導體、電子及精密組裝製造商，提供創新的 流體點膠 、 表面塗覆 、 等離子處理 及 選擇性焊接 解決方案，保護敏感電子元件並提供可靠的使用壽命。四十多年來，在全球範圍內提供卓越的工程和應用服務，協助客戶取得成功。 關於 Nordson 公司 Nordson Corporation（NASDAQ：NDSN）是一家創新型精密技術的公司，通過一個以部門為主導的創業型組織，利用可擴展的成長框架，以領先的利潤和回報實現頂級增長。公司依託直接銷售模式和應用專業知識，透過各種關鍵應用為全球客戶提供服務。其多元化的終端市場包括非耐用消費品、醫療、電子和工業終端市場。公司創立於1954年，總部位於美國俄亥俄州韋斯特萊克，目前在全球35個國家/地區設有運營網站和技術支援辦公室。造訪Nordson官方網站： 。 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
